Early HIV vaccine trial shows promise – but still a long way to go

NCT ID NCT04844775

Completed ⭐️ VACCINE ⭐️ Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial tested a new HIV vaccine in 68 healthy adults to see if it is safe and triggers an immune response. The vaccine uses a DNA-based approach combined with an HIV protein to train the body to fight the virus. While early results are encouraging, this is just the first step – much more research is needed to know if it can actually prevent HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIV vaccine (DREP-HIV-PT1 and CN54gp140+MPLA-L)
What this could lead to: If successful, this could point toward a safe and effective HIV vaccine that prevents infection.
What could go wrong: This is a very early Phase 1 trial with only 68 participants. It only tests safety and immune response, not whether the vaccine actually prevents HIV. Many early vaccines fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULTS

Contacts and locations

Locations

CHUV

Lausanne, Canton of Vaud, 1011, Switzerland
CIC Cochin

Paris, Paris Cedex 14, 75679, France
Chelsea and Westminster Hospital

London, SW10 9NH, United Kingdom
Hôpital Henri Mondor

Créteil, Paris, 94010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.